Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants (ReCoRDBCN)

4 de noviembre de 2026 actualizado por: Hospital Clinic of Barcelona

ReCoRD-BCN Trial: Multicentre, Double-blind Randomized Controlled Trial Evaluating the Effect of Cord Blood-derived Red Blood Cell Transfusion on Retinopathy of Prematurity in Extremely Preterm Infants

Anemia is a condition in which there are not enough red blood cells to carry oxygen throughout the body. It is very common in extremely preterm infants (born before 28 weeks of pregnancy), and many of these babies require red blood cell transfusions during their hospital stay.

Currently, transfusions are given using red blood cells donated by adults. An alternative option is to use red blood cells collected from umbilical cord blood, which may be more similar to a newborn's own blood. This approach has been used in some neonatal units with encouraging results and no reported safety concerns.

This study aims to determine whether transfusion with umbilical cord blood improves clinical outcomes and reduces potential side effects compared to standard adult donor blood transfusion in extremely preterm infants. We hypothesize that umbilical cord blood transfusion will be at least as safe as adult donor blood and may provide clinical benefits.

Infants admitted to neonatal units in Catalonia will participate. If parents agree, their baby will be randomly assigned to receive either compatible umbilical cord blood or compatible adult donor blood if a transfusion becomes necessary. Babies will only receive a transfusion if they clinically need one. If cord blood is not available at the time of transfusion, the baby will receive compatible adult donor blood regardless of the assigned group.

To evaluate the response to treatment, small blood samples will be collected at birth, at one month of life, and 24 hours after any transfusion. These samples are taken at the same times as routine blood tests, so participation does not require additional needle sticks. The amount of blood collected is minimal (about 0.2 mL per sample).

Participation will continue until the baby reaches 40 weeks of postmenstrual age.

Descripción general del estudio

Descripción detallada

Neonatal anemia is a common condition in extremely preterm infants (born before 28 weeks of gestation) and is associated with significant health risks. Despite the implementation of evidence-based strategies to reduce anemia, such as delayed umbilical cord clamping and cord milking, many extremely preterm infants still require red blood cell transfusions during the first weeks of life due to a multifactorial decline in hemoglobin levels.

Currently, red blood cell transfusions for these infants use blood from adult donors. Transfusion of adult donor blood has been associated with complications linked to fluctuations in tissue oxygen levels, including retinopathy of prematurity and bronchopulmonary dysplasia. One key factor contributing to these complications is the lower proportion of fetal hemoglobin (HbF) in adult donor blood compared to the infant's natural blood. HbF has a higher affinity for oxygen and releases oxygen more slowly, whereas adult hemoglobin (HbA) delivers oxygen more rapidly to tissues, increasing the risk of oxygen toxicity. Additionally, adult donor blood may contain trace amounts of heavy metals, which could potentially affect extremely preterm infants, although this has not been formally studied.

Red blood cell concentrates derived from umbilical cord blood (CB-RBC) provide an alternative that is closer to the infant's own blood composition. CB-RBC transfusions contain higher levels of HbF, which may reduce tissue oxygen stress. Pilot studies in our center have shown that CB-RBC transfusions are feasible, safe, and effective. In one preliminary study, ten extremely preterm infants (<28 weeks gestation) received a total of 23 CB-RBC transfusions without adverse reactions, indicating that this approach is safe in clinical practice. However, medium- and long-term benefits of CB-RBC transfusions remain unclear.

Recent research shows that higher HbF levels are inversely correlated with morbidities related to tissue hyperoxygenation, such as retinopathy of prematurity. Studies in Italy, including those by Teofili et al., have shown encouraging trends toward reducing severe retinopathy, although small sample sizes prevented statistical significance. These findings support the need for a larger randomized multicenter trial to evaluate clinical outcomes more conclusively.

This study is a randomized multicenter clinical trial coordinated among all major level 3A and 3B public neonatal units in the Barcelona area, with unanimous support from participating units. Eligible infants will be randomly assigned to receive either CB-RBC transfusions or standard adult donor red blood cell transfusions if a transfusion is clinically indicated. Transfusions will only be performed when medically necessary. If cord blood is not available at the time of transfusion, compatible adult donor blood will be used regardless of assigned group.

To assess the effects of transfusion, small blood samples will be collected at birth, at one month of age, and 24 hours after any transfusion. Blood collection follows routine clinical practice, and volumes are minimal (~0.2 mL per sample). All procedures are designed to minimize risk and discomfort for participants.

Study Hypothesis: We hypothesize that transfusion with cord blood red blood cell concentrates will reduce retinopathy of prematurity, compared to transfusions with standard adult donor red blood cells.

The results of this study aim to provide strong evidence regarding the clinical benefits of CB-RBC transfusions in extremely preterm infants, including the potential to reduce transfusion-related complications and improve outcomes. If successful, this approach could be implemented more widely to enhance neonatal care for this vulnerable population

Tipo de estudio

Intervencionista

Inscripción (Estimado)

280

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Miguel Maria Alsina Casanova, MD
  • Número de teléfono: 7503 +34932275600
  • Correo electrónico: mmalsina@clinic.cat

Copia de seguridad de contactos de estudio

  • Nombre: Dinara Smarkanova, MD
  • Número de teléfono: 6563 +34935573500
  • Correo electrónico: dsamarkanova@bst.cat

Ubicaciones de estudio

      • Barcelona, España, 08028
        • Hospital Clínic de Barcelona - Maternitat
        • Contacto:
          • Miguel Maria Alsina Casanova, MD
          • Número de teléfono: 7447 +34932275600
          • Correo electrónico: mmalsina@clinic.cat
        • Investigador principal:
          • Miguel Ramón Jimenez, MD
        • Investigador principal:
          • Fátima Camba Longueira, MD
        • Investigador principal:
          • María José García Borau, MD
        • Investigador principal:
          • Marta Ocaña Rico, MD
        • Investigador principal:
          • Mònica Domingo Puiggròs, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

5 meses a 6 meses (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Signed informed consent obtained from parents or legal guardians.
  • Gestational age at birth < 28 weeks or birth weight < 1000 g.
  • Admission to one of the participating neonatal intensive care units (NICUs) in the Barcelona area.

Exclusion Criteria:

  • Prior red blood cell transfusion during the fetal or neonatal period.
  • Maternal-fetal immunization (e.g., isoimmunization).
  • Fetal hydrops.
  • Major congenital malformations.
  • Congenital infections.
  • Immediate need for blood before randomization (e.g., hemorrhagic shock, consumptive coagulopathy).
  • Participation in another clinical trial that could interfere with the primary outcome.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cord Blood-Derived Red Blood Cell Transfusion

Extremely preterm infants randomized to this arm will receive red blood cell transfusions derived from umbilical cord blood (CB-RBC) when a transfusion is clinically indicated according to standard neonatal guidelines. If compatible cord blood units are not available at the time of transfusion, standard adult donor red blood cells may be used.

Neonates receive transfusions of red blood cells derived from allogeneic umbilical cord blood, ABO/RhD compatible.

Dosage: 15-20 mL/kg per transfusion, administered according to clinical indication and availability.

If cord blood is not available at the time of transfusion, adult donor red blood cells (CH-SA) are given instead.

Monitoring: Vital signs, complete blood count, hematocrit and fetal hemoglobin (HbF) are recorded before and after transfusion.

Otros nombres:
  • CH-SCU
Comparador activo: Adult Donor Red Blood Cell Transfusion

Extremely preterm infants randomized to this arm will receive standard adult donor red blood cell transfusions when a transfusion is clinically indicated according to standard neonatal guidelines.

Neonates receive transfusions of red blood cells derived from adult donors, ABO/RhD compatible.

Dosage: 15-20 mL/kg per transfusion, administered according to clinical indication and the protocol of each neonatal unit.

Transfusions are performed only when medically necessary. Monitoring: Vital signs, complete blood count, hematocrit and fetal hemoglobin (HbF) are recorded before and after transfusion.

Otros nombres:
  • CH-SA

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Retinopathy of prematurity stage 2 or more
Periodo de tiempo: From birth until 40 weeks postmenstrual age.

The primary outcome is to evaluate the incidence of Retinopathy of prematurity (stage 2 or more) diagnosed according to the International Classification of Retinopathy of Prematurity, assessed by ophthalmologists blinded to group allocation using ophthalmoscopy and the Catalonia Ophthalmic Telemedicine Network (RTOC).

From birth until 40 weeks postmenstrual age.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Bronchopulmonary dysplasia (BPD, any grade)
Periodo de tiempo: From birth until 36 weeks postmenstrual age or hospital discharge, whichever occurs first.

To evaluate the incidence of Bronchopulmonary dysplasia (BPD, any grade) defined as the need for oxygen therapy or any respiratory support at 36 weeks postmenstrual age (PMA). Classified according to Jensen et al. (2019), assessed at 36 weeks PMA.

From birth until 36 weeks postmenstrual age or hospital discharge, whichever occurs first.
Fetal hemoglobin (HbF) threshold at one month associated with clinical outcomes
Periodo de tiempo: At one month of life.

To evaluate the fetal haemoglobin (HbF) percentage cutoff at one month of life that best correlates with a reduction in the composite outcome of retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), or death, as well as with each outcome individually. Due to limited availability of cord blood units (CB-RBC), some infants assigned to this group may receive adult donor red blood cells. This analysis aims to identify protective or critical HbF thresholds for the development of ROP and BPD.

At one month of life.
Oxygen-free days within 90 days post-randomization
Periodo de tiempo: Up to 90 days after randomization.

To evaluate the impact of cord blood-derived red blood cell transfusion (CB-RBC) versus standard adult donor red blood cell transfusion (AD-RBC) on intermediate outcomes, specifically the number of oxygen-free days during the 90 days following randomization.

Up to 90 days after randomization.

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Hematologic parameters post-transfusion (1)
Periodo de tiempo: Pre-transfusion, 24 hours post-transfusion, and at 1 month of age

Assessment of transfusion efficacy via changes in total hematocrit.An increment in hematocrit by 12 ± 5 points 24 hours after the transfusion will be considered effective. This analysis aims to demonstrate non-inferiority of CB-RBC vs AD-RBC.

Pre-transfusion, 24 hours post-transfusion, and at 1 month of age
Hematologic parameters post-transfusion (2)
Periodo de tiempo: Pre-transfusion, 24 hours post-transfusion, and at 1 month of age

Assessment of transfusion efficacy via changes in total hemoglobin. An increment in total hemoglobin by 4 ± 2 g / dL 24 hours after the transfusion will be considered effective. Samples will be analysed by microhematocrit method. This analysis aims to demonstrate non-inferiority of CB-RBC vs AD-RBC.

Pre-transfusion, 24 hours post-transfusion, and at 1 month of age
Fetal hemoglobin (HbF) percentage evolution
Periodo de tiempo: At birth, 24 hours post-transfusion, and 1 month of age

Measure changes in HbF percentage over time (at birth, pre- and post-transfusion, and at 1 month), evaluating its association with intermediate and clinical outcomes.

At birth, 24 hours post-transfusion, and 1 month of age
Red blood cell transfusion requirements (1)
Periodo de tiempo: From birth until 36 weeks PMA or hospital discharge

Total volume of transfusions (mililiters) received until 36 weeks PMA or hospital discharge, comparing CB-RBC vs AD-RBC.

From birth until 36 weeks PMA or hospital discharge
Red blood cell transfusion requirements (2)
Periodo de tiempo: From birth until 36 weeks PMA or hospital discharge

Total number of transfusions received until 36 weeks PMA or hospital discharge, comparing CB-RBC vs AD-RBC.

From birth until 36 weeks PMA or hospital discharge
Bone marrow regeneration parameters
Periodo de tiempo: 1 month of life

Reticulocyte counts will be measured at 1 month of life as an indicator of marrow regeneration

1 month of life
Iron metabolism values
Periodo de tiempo: 1 month of life

Ferritin levels at 1 month of life will be measured as an indicator of iron metabolism

1 month of life

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Miguel Maria Alsina Casanova, MD, Hospital Clinic of Barcelona
  • Director de estudio: Dinara Smarkanova, MD, Banc de Sang i Teixits
  • Investigador principal: María José García Borau, MD, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  • Investigador principal: Marta Ocaña Rico, MD, Germans Trias i Pujol Hospital
  • Investigador principal: Miguel Ramón Jiménez, MD, Hospital Sant Joan de Deu
  • Investigador principal: Fátima Camba Longueira, MD, Hospital Vall d'Hebron
  • Investigador principal: Mònica Domingo Puiggròs, MD, Hospital Parc Taulí

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

1 de diciembre de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2029

Fechas de registro del estudio

Enviado por primera vez

16 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

27 de marzo de 2026

Publicado por primera vez (Actual)

31 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir